Reminder - please complete the survey if you are any of the above treatments. At the moment we have only had a few responses.
By completing this survey you are part of the process that may help patients gain access to these treatments in lots of countries. Your experience as a patient is a vitally important part of this process.
The survey will be open until midnight Pacific Time on Friday, February 28th, 2020 and should only take 10 minutes of your time.
Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL
Acalabrutinib (Calquence) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL
Acalabrutinib (Calquence) monotherapy for first-line treatment of CLL/SLL
Acalabrutinib (Calquence) monotherapy for treatment of relapsed or refractory CLL/SLL
Here is the link, it should take about 10 minutes.
Because this is a subjective survey of people's experiences with these treatments, not a trial of any sort.
The answers are helpful when completing Health Technology Appraisals and we can say things along the lines of "x% had no side effects at all from xxx". We can also say what were the challenges for patients, so complying with the guidelines for the V ramp up might put some people off and we like to know those things.
Hi Jackie, this sounds very interesting. when do you think results will be available and how can we access those, even if we have not been able to answer the survey (as not treated yet, for example)?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.